3D MRI Technique for Rheumatoid Arthritis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new MRI technique, 3D DL oZTEo, to better detect bone damage in the hands of individuals with inflammatory arthritis, such as rheumatoid arthritis. The goal is to determine if this method improves the detection and management of these changes compared to regular x-rays and MRIs. Suitable participants have had hand x-rays showing bone damage in the past 3-6 months and are scheduled for a hand MRI at Mayo Clinic Rochester.
As an unphased study, this trial provides a unique opportunity to advance medical imaging techniques for improved arthritis care.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this MRI technique is safe for detecting osseous erosions in rheumatoid arthritis?
Research has shown that the 3D DL oZTEo MRI technique is easy for patients to handle. The FDA has already approved this type of MRI, indicating a strong safety record for its intended use. Importantly, no major reports of negative effects have been linked to this technology. It improves images of bones without using radiation, unlike traditional X-rays, making it a safer choice for assessing joint and bone health, especially in conditions like rheumatoid arthritis.12345
Why are researchers excited about this trial?
Researchers are excited about the 3D DL Ozteo technique for rheumatoid arthritis because it uses a cutting-edge MRI pulse sequence called oZTEo. Unlike traditional imaging methods, oZTEo is designed to provide clearer, more detailed images of joints affected by rheumatoid arthritis without the need for additional contrast agents. This could lead to faster and more accurate assessments of joint damage and inflammation, potentially transforming how doctors monitor the progression of the disease and adjust treatments. By enhancing the precision of MRI scans, this technique holds the promise of improving patient care and outcomes.
What evidence suggests that this 3D MRI technique is effective for detecting osseous erosions in rheumatoid arthritis?
Research shows that the 3D DL Ozteo MRI technique, which participants in this trial will receive, holds promise for detecting bone changes in individuals with inflammatory arthritis, such as rheumatoid arthritis. Studies have found that advanced MRI methods, including this one, effectively identify bone damage in the hands. This damage is crucial because it can guide doctors in choosing the best treatment and sometimes even aid in diagnosing the condition. By accurately detecting these changes, 3D DL Ozteo could potentially enhance rheumatoid arthritis treatment. Although researchers are still studying this MRI technique, early results suggest improvements in patient care.13467
Who Is on the Research Team?
Naveen Murthy, MD
Principal Investigator
Mayo Clinic
Are You a Good Fit for This Trial?
This trial is for patients with inflammatory arthritis, such as rheumatoid arthritis, who need their hand bones checked for damage. The study will use a new MRI technique to spot bone erosion.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
MRI Examination
Participants undergo MRI examination with the addition of the 3D DL oZTEo sequence to detect osseous changes
Follow-up
Participants are monitored for any immediate reactions or complications following the MRI examination
What Are the Treatments Tested in This Trial?
Interventions
- 3D DL Ozteo
3D DL Ozteo is already approved in European Union, United States for the following indications:
- Bone imaging
- Detection of osseous erosions
- Orthopedic imaging
- Bone imaging
- Detection of osseous erosions
- Orthopedic imaging
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
GE Healthcare
Industry Sponsor
Fotis Vlachos
GE Healthcare
Chief Marketing Officer since 2024
PhD in Molecular Biology and Biochemistry from the University of Massachusetts, MBA from the Wharton School of the University of Pennsylvania
Peter J. Arduini
GE Healthcare
Chief Executive Officer since 2022
MBA from Northwestern University, BSc in Marketing from Susquehanna University